Assessing the role of local inflammatory, fibroproliferative, and osteogenic biomarkers in Systemic Sclerosis related Interstitial Lung Disease.
Recruiting
- Conditions
- CRESTlung fibrosisscleroderma100038161002496710047043
- Registration Number
- NL-OMON49016
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
• Age 18-70 years
• Written informed consent
• Formal diagnosis of Systemic Sclerosis based on ACR/EULAR criteria
• Formal diagnosis of interstitial lung disease (for 15 of 20 included
patients)
Exclusion Criteria
• Patients who are mentally incompetent
• Vascular event or chemotherapy in the preceding 3 months
• Inflammation of unknown origin
• Other lung disease present
• Use of anti-inflammatory medication or antibiotics
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link inflammatory and osteogenic biomarkers to SSc-ILD progression?
How do fibroproliferative biomarkers in SSc-ILD compare with standard-of-care treatment outcomes?
Which biomarkers in the ILD-SSc study predict patient response to anti-fibrotic therapies?
What adverse events are associated with targeting TGF-β and Wnt pathways in SSc-ILD patients?
Are there combination therapies involving IL-1 inhibitors and antifibrotics for CREST syndrome lung fibrosis?